GoodRx (Nasdaq: GDRX) announced it is working with ARS Pharmaceuticals to offer the lowest discounted cash price for neffy in ...

Neffy, an intranasal formulation of epinephrine, is now available for emergency treatment of type I allergic reactions.

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS ...

Whether it’s allergies, a sinus infection or runny nose, many people turn to nasal sprays for quick relief. Now, there’s ...

ARS Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) for a1 mg dose of nasal spray neffy, to treat ...

Whether it’s allergies, a sinus infection or runny nose many people turn to nasal sprays for quick relief. And now, there’s ...

We came across a bullish thesis on ARS Pharmaceuticals (SPRY) on Value Degen’s Substack by Unemployed Value Degen. In this ...

The submission of the neffy 1 mg sNDA follows the FDA approval of neffy (2 mg) on August 9, 2024, for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing 30 kg ...

Nefertiti Harris, known as Neffy, was beaten to death by her mother, Latasha Mott, Jan. 6, Syracuse police said. Mott hid the ...

Neffy is a small molecule commercialized by ARS Pharmaceuticals, with a leading Pre-Registration program in Anaphylaxis.

Amphastar Pharmaceuticals has seen significant growth since its IPO, with its stock price increasing over 500%. Learn more ...